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In this article, we first briefly outline the function of G protein coupled receptors
in cancer, and then specifically examine the roles of the seven transmembrane G
protein coupled Endothelin B receptor (Ednrb) and the G proteins, GNAQ and GNA11,
in both melanocyte development and melanoma. Ednrb plays an essential role in
melanocyte development. GNAQ and GNA11 are oncogenes when mutated in certain
types of melanocytic lesions, being extremely frequent in uveal melanoma, which forms
from melanocytes located in the eye. Previously, we reported that in mice, Schwann
cell precursor derived melanocytes colonize the dermis and hair follicles, while the
inter-follicular epidermis is populated by other melanocytes. A pattern has emerged
whereby melanocytes whose activities are affected by gain-of-function mutations of
the Endothelin 3 ligand and Gαq/11 are the same subset that arise from Schwann
cell precursors. Furthermore, the forced expression of the constitutively active human
GNAQQ209L oncogene in mouse melanocytes only causes hyper-proliferation in the
subset that arise from Schwann cell precursors. This has led us to hypothesize that
in Schwann cell precursor derived melanocytes, Ednrb signals through Gαq/11. Ednrb
is promiscuous and may signal through other G protein alpha subunits in melanomas
located in the inter-follicular epidermis.
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INTRODUCTION
G-protein coupled receptors (GPCRs) are one of the largest and most diverse membrane protein
families, consisting of over 800 members and comprising 30% of drug discovery targets. GPCRs
function by detecting a wide spectrum of extracellular signals and ligands, which generate
conformational changes in the GPCR structure and cause the activation of signaling networks
inside the cell. The non-sensory GPCRs are classified into four main families. These include
the rhodopsin-like receptors, which are the most numerous, the secretin-like receptors, the
metabotropic glutamate and pheromone receptors, and the frizzled receptors (reviewed in
Venkatakrishnan et al., 2013).
The structure of seven transmembrane GPCRs can be divided into three regions: extracellular,
transmembrane, and intracellular. The extracellular region consists of the N terminus and three
extracellular loops (ECL1–ECL3). The transmembrane (TM) region consists of a core structure of
seven alpha helices (TM1–TM7). The intracellular region contains three intracellular loops (ICL1–
ICL3), an intracellular amphipathic helix (H8), and the C terminus. The activation of GPCRs begins
with the binding of a ligand to the extracellular portions of the receptor, which causes a small
conformational change in the TM core. This ultimately leads to larger structural rearrangements
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at the transmembrane- intracellular domain interface, which
alters the interactions of signaling effectors, such as G proteins,
GPCR kinases, and arrestins, with the cytoplasmic portions of
the receptor. Different ligands produce different conformational
states within a GPCR, such as full agonists, partial agonists,
inverse agonists, and allosteric modulators. Each of these can
bring about different downstream effects. The active state of a
GPCR is defined as the conformation of the receptor that couples
to and stabilizes an effector molecule [reviewed in (Cabrera-Vera
et al., 2003; Venkatakrishnan et al., 2013)].
GPCRs mainly signal through heterotrimeric G proteins,
which contain three separate subunits: α, β, and γ. In its
inactive state, the α subunit is bound to a guanine diphosphate
molecule (GDP) and the β and γ subunits in a complex tethered
to the cytosolic side of the cell membrane. When a GPCR
is activated by ligand binding, it recruits a heterotrimeric G
protein, which triggers the release of GDP and the binding of a
guanine triphosphate molecule (GTP) on the Gα subunit. Key
residues for GPCR-G protein couplings have been identified
within the N termini (McFadzean et al., 1989; Blahos et al.,
1998), α2-helices, α2-β4 loop regions (Lee et al., 1995; Onrust
et al., 1997), α4-helices, and α4-β6 loop regions (Bae et al.,
1997) of the receptor. The GTP-bound Gα subunit dissociates
from the receptor and Gβγ subunits to activate downstream
effectors. There are five classes of Gα protein (Gαs, Gαq, Gαi,
Gα12/13, and the newly discovered Gαv) and the GTP-bound
conformations of each class interact with different canonical
downstream effectors. Some GPCRs signal through more than
one type of Gα protein, which further increases complexity. In
addition, the Gβγ subunits can also act on effectors. The activity
of Gα is self-limited by the intrinsic GTPase activity of its Ras-
like domain, which hydrolyses GTP back to GDP and prevents
further interaction of Gα with its effector. This inactivation step
is modulated by Regulators of G-protein signaling (Rgs) proteins,
which are GTPase accelerating proteins (GAPs). Some effectors
also act as GAPs for Gα, such as the phospholipase C effector for
Gαq class α subunits [reviewed in (Conklin and Bourne, 1993;
Wess, 1997; Yang et al., 1999; Cabrera-Vera et al., 2003; Oka et al.,
2009; Kimple et al., 2011; Sánchez-Fernández et al., 2014)].
G PROTEIN COUPLED PATHWAYS IN
CANCER
G-protein coupled receptors regulate many key biological
functions, such as differentiation, cell proliferation, cell
migration, and metabolic activity, thus it is not surprising
that GPCRs play a role in tumorigenesis. In general, there
are four mechanisms by which G protein coupled pathways
drive tumorigenesis: excess ligand availability, excess GPCR
expression, activating mutations in GPCRs, and activating
mutations in Gα proteins.
Many potent mitogens such as thrombin, lysophosphatidic
acid (LPA), gastrin-releasing peptide (GRP), endothelins, and
prostaglandins, stimulate cell proliferation by acting on their
cognate GPCR in various cell types (Gutkind, 1998; Marinissen
and Gutkind, 2001; Rozengurt et al., 2002; Mills and Moolenaar,
2003). In 1991, it was reported that over-expression of muscarinic
cholinergic receptors (mAChRs) in NIH3T3 cells was not
sufficient for oncogenic transformation. However, when the cells
were treated with an excess of carbachol ligand, foci were readily
induced. This result showed that normal GPCRs can promote
ligand-dependent neoplastic transformation when stimulated by
the unrestricted availability of their ligand (Gutkind et al., 1991).
In addition, malignancies such as colon carcinoma (Gao et al.,
2006), squamous cell carcinoma (SCC) of the lung (Gugger et al.,
2008), basal cell carcinoma (Tanese et al., 2008), hepatocellular
carcinoma (Yamamoto et al., 2003), prostate cancer (Weigle
et al., 2004), breast cancer (Mihai et al., 2006), and glioblastoma
multiforme (Shashidhar et al., 2005) have been reported to over-
express GPCRs.
Activating mutations in GPCRs represent another
tumorigenic route. Mutations in the thyroid-stimulating
hormone receptor are found in ∼30% of thyroid adenomas
(Parma et al., 1993). Mutations have also been reported in
Smoothened (SMO), glutamate metabotropic receptors (GRMs),
members of the adhesion family of GPCRs, and receptors
for bioactive lipid mediators such as LPA and sphingosine-
1-phosphate (S1P) which tend to accumulate in the tumor
microenvironment. In 2010, a ground-breaking study revealed
an unexpectedly high frequency of somatic mutations in genes
encoding GPCRs in breast, lung, ovarian, and prostate cancer,
including LPHN3, GRM8, CMKLR1, MAS1L, AGTRL1, and
PTGFR (Kan et al., 2010). It was estimated that 20% of all cancers
bear somatic mutations in GPCRs.
Finally, pathway activation can occur through mutations in
Gα subunits. Because the Gα subunit must inactivate itself
through the hydrolysis of GTP to GDP, mutations that reduce
the function of the Ras-like GTPase domain paradoxically lead
to constitutive active signaling. In certain cellular contexts, this
generates oncogenic transformation. This was first discovered
in 1989 when somatic activating mutations in Gαs were found
in growth hormone-secreting human pituitary tumors (Landis
et al., 1989). Recently, Gαs was reported to be mutated in 3.8%
of 28,961 tumor samples, according to the Catalogue of Somatic
Mutations in Cancer (COSMIC) database (Forbes et al., 2010).
Somatic mutations causing constitutive activity of Gα proteins
have been found in other types of cancers as well (Lyons et al.,
1990; Van Raamsdonk et al., 2009b, 2010). Common to all these
lesions is that the mutations occur in the Ras-like GTPase domain
of Gα at the perfectly conserved glutamine and arginine residues
that directly contact the gamma phosphate of GTP, stabilizing it
for hydrolysis (Landis et al., 1989; Markby et al., 1993; Farfel et al.,
1999).
Gαq/11 SUBUNITS IN MELANOCYTE
DEVELOPMENT AND MELANOMA
Melanomas arise from pigment producing cells called
melanocytes in mammals. Immature melanocytes, melanoblasts,
originate in the neural crest, either directly in an early stream, or
indirectly from Schwann cell precursors lining developing nerves
(Adameyko et al., 2009). During embryogenesis, melanoblasts
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FIGURE 1 | (A) Components of the hypothesized Endothelin signaling pathway. Constitutively active mutations found in GNAQ and GNA11 in human melanocytic
lesions are boxed in red. (B) We hypothesize that Schwann cell precursor derived melanocytes transmit endothelin signals through Gαq/11. Schwann cell precursor
derived melanocytes are also susceptible to developing melanocytic lesions when either GNAQ or GNA11 are mutated to their constitutively active forms. This
melanomagenic pathway gives rise to non-epithelial associated lesions. Other G protein alpha subunits may transmit endothelin signals in epithelial associated
melanomas.
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migrate through the dermis along the dorsal-ventral axis. Some,
but not all of the melanoblasts, will enter the epidermis. There
they can choose to migrate into hair follicles or persist in
between hair follicles in the “inter-follicular” epidermis. Other
melanoblasts never enter the epidermis. These non-epithelial
melanocytes remain in the dermis or migrate into the uveal
tract of the eye or the leptomeninges of the central nervous
system.
The majority of human melanomas arise from melanocytes
located in the inter-follicular epidermis. The rest arise from non-
epithelial melanocytes, which as a group are characterized by
frequent oncogenic mutations in the heterotrimeric G protein
alpha subunits, GNAQ and GNA11, which encode Gαq and Gα11
(Van Raamsdonk et al., 2009b, 2010; Küsters-Vandevelde et al.,
2010) The importance of these two proteins in melanocytes first
became apparent during a study of a set of mouse mutants
with a darker dermis (Dsk1, Dsk7, Dsk10), obtained during
an ENU (N-ethyl-N-nitrosourea) mutagenesis screen of 30,000
mice (Hrabé de Angelis et al., 2000; Fitch et al., 2003; Van
Raamsdonk et al., 2004). These mice carried hyper-active, but not
constitutively active, single amino acid substitution mutations
in either Gnaq or Gna11 at isoleucine 63, valine 179, or
phenylalanine 335. These mutations increased the number of
melanoblasts in the embryo beginning immediately after the
first commitment of these cells to the melanocyte lineage. The
increased melanocytes persisted in the dermis throughout the
life of the mice, but did not cause tumors. The Gnaq and
Gna11 dark dermis mutations acted additively, darkening the
dermis in a quantitative and step-wise fashion as the number
of mutant Gnaq and Gna11 alleles increased, indicating that
the read-out of Gαq/11 signaling can be quantitative. Strikingly,
the inter-follicular epidermis of the tail, which is pigmented,
was unaffected by the mutations, even when all four Gnaq and
Gna11 alleles were replaced with gain-of-function Dsk versions.
The gain-of-function alleles partially rescued the reduction in
melanoblast numbers caused by heterozygous loss of the c-
Kit tyrosine kinase receptor, Pax3 transcription factor, and
endothelin B receptor, Ednrb. However, homozygous loss of
Ednrb prevented all Gαq and Gα11 generated skin darkening.
Based upon previous in vitro work (Okamoto et al., 1997; Doi
et al., 1999; Imamura et al., 2000), this led to the hypothesis
that Endothelin receptor B, a G protein coupled receptor, signals
through Gαq/11 in melanocytes.
The mutations in GNAQ and GNA11 in human melanocytic
lesions are somatic, mutually exclusive, and occur at two
hotspots, glutamine 209 and arginine 183, which causes
constitutive activity. 50%–85% of non-epithelial melanocytic
lesions are affected by these mutations, and include lesions in
the dermis, called blue nevi, leptomeningeal melanocytomas,
uveal nevi, and uveal melanomas. The two genes are mutated
with unequal frequency in each type of lesion. GNAQ mutations
are 7.9 times more frequent in dermal lesions, 4.6 times more
frequent in leptomeningeal melanocytomas, and 1.4 times more
frequent in primary uveal melanomas, compared with GNA11
mutations (Küsters-Vandevelde et al., 2010; Van Raamsdonk
et al., 2010; Gessi et al., 2012; Küsters-Vandevelde et al., 2014).
Conversely, GNA11 mutations are 2.6 times more frequent
than GNAQ mutations in uveal melanoma metastases (Van
Raamsdonk et al., 2010). Given their presence in uveal nevi,
GNAQ and GNA11 mutations are hypothesized to be early events
in uveal melanomagenesis (Van Raamsdonk et al., 2010). Q209
mutations are much more frequent than R183 mutations, and are
predicted to have a greater inhibitory effect on the GTPase activity
of Gαq/11 (Berman et al., 1996; Orth et al., 2009; Van Raamsdonk
et al., 2010) (Figure 1A).
Mutations in either gene are extremely rare in human
melanomas located in the epidermis. The COSMIC database
v72 reported four patients with GNAQ mutations among 1,696
entries (0.2%) for superficial spreading, lentigo maligna, nodular,
and otherwise unspecified malignant melanomas of the skin.
Consistent with this, the forced expression of GNAQQ209L
in mouse melanocytes caused cell loss in the inter-follicular
epidermis, in contrast to the hyper-proliferation observed in
the dermis, hair follicles, leptomeninges, and uveal tract (Huang
et al., 2015). Fate mapping during mouse development has shown
that Schwann cell precursor derived melanoblasts migrate to the
dermis and hair follicles, but not the inter-follicular epidermis
of the tail (Deo et al., 2013). Therefore, we hypothesize that
the developmental lineage of a melanocyte determines whether
constitutive activity of Gαq and Gα11 is oncogenic (Figure 1B).
The first effector of Gαq class α subunits to be identified
was phospholipase C (PLC). PLC cleaves phospholipid
phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl glycerol
(DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 diffuses in the
cytoplasm and binds to receptors such as calcium channels in the
endoplasmic reticulum, releasing calcium as a second messenger.
Calcium and DAG also activate protein kinase C, which can
phosphorylate RAF in the MAP kinase pathway. One of the
primary effects of oncogenic Gαq and Gα11 is the activation of
the MAP kinase pathway and the phosphorylation of MEK and
ERK (Van Raamsdonk et al., 2009b, 2010). In a randomized,
phase II trial of the MEK inhibitor, selumetinib, treatment
improved progression-free survival, and the response rate to
chemotherapy, but unfortunately did not lead to improvement
in overall survival (Carvajal et al., 2014). PKC activity may
have additional effects, because PKC inhibition decreased NFkB
signaling (Wu et al., 2012) and combined PKC and MEK
inhibition is more efficacious at inhibiting MAP-kinase pathway
activation, halting proliferation, and inducing apoptosis in vitro
(Chen et al., 2014). A phase Ib/II combination trial of a MEK
inhibitor, MEK162, plus the PKC inhibitor, AEB071, has been
initiated (NCT01801358).
MEK inhibition has been reported to lead to PI3K/AKT
up-regulation, which may contribute to tumor resistance
(Babchia et al., 2010). A phase II trial will compare the MEK
inhibitor, trametinib, alone or trametinib plus the AKT inhibitor,
GSK2141795 (NCT01979523). Additionally, a phase 1b trial
will be launched using the PKC inhibitor sotrastaurin plus the
PI3K-alpha inhibitor, BYL719 (Shoushtari and Carvajal, 2014).
Alternative effectors mediate Gαq activity independently of PLC,
revealing unanticipated complexity. Oncogenic Gαq stimulates
the transcriptional co-activator, YAP, through a Trio-Rho/Rac
signaling circuitry that promotes actin polymerization, in a
pathway that is independent of both PLC and the canonical
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Hippo pathway (Feng et al., 2014; Yu et al., 2014). This provides
yet another rational therapeutic avenue for uveal melanoma.
YAP dephosphorylation and nuclear translocation may stimulate
melanoma by increasing Notch signaling, through up-regulation
of the Notch ligand, JAG-1 (Liu et al., 2015).
ENDOTHELIN SIGNALING IN
MELANOCYTE DEVELOPMENT
Endothelin receptors are GPCRs that belong to the rhodopsin-
like class. In mammals, there are two Endothelin receptors, type
A and B, and three 21 amino acid long Endothelin ligands, Edn1,
Edn2, and Edn3, which are processed to their mature forms
by Endothelin converting enzymes 1 and 2 (Ece-1, Ece-2). The
loss of Endothelin receptor B (Ednrb) in mice causes a severe
reduction in melanoblast numbers, while Endothelin receptor A
(Ednra) knockout does not produce a pigmentation phenotype
(Baynash et al., 1994; Hosoda et al., 1994; Clouthier et al.,
1998). Thus, the effect of endothelin signaling in melanocyte
development appears to be transduced by Ednrb. Ednrb has an
equal affinity for all three of the Endothelin ligands (Sakurai et al.,
1990). Edn3 and Ece-1 mutant mice have a very similar phenotype
compared to Ednrb mutant mice, neatly linking the three proteins
during development (Baynash et al., 1994; Yanagisawa et al.,
1998).
During mouse embryogenesis, Ednrb is expressed in
melanoblasts by the time they are committed to the melanocyte
cell fate (Lee et al., 2003). In Ednrb null embryos, melanoblasts
appear in the mesenchyme directly adjacent to the dorsal
neural tube, sometimes referred to as the melanoblast staging
area, but then are lost in an anterior to posterior progression
(Hosoda et al., 1994; Lee et al., 2003). A similar result was found
studying Schwann cell precursor derived melanoblasts around
cranial nerves IX–X in Ednrb null mouse embryos. Melanoblasts
appeared in the mutants, but were greatly reduced in number
and did not break contact with the nerve (Adameyko et al.,
2012). A temporally regulated Ednrb expression system in mice
demonstrated that melanoblasts that have migrated into the
epidermis do not require Ednrb signaling to persist there (Shin
et al., 1999). Thus, the primary role of Ednrb during mouse
development seems to be to support and direct newly created
melanoblasts when they are migrating in the dermis, which
all melanoblasts must do. It is important to note that a few
melanoblasts can survive without endothelin signaling in the
head and lower body, leading to small patches of pigmented fur
in those areas on an otherwise white background (Hosoda et al.,
1994). Interestingly, melanoblasts in the midbrain region, which
arise independently of nerves, are affected less by Ednrb loss and
therefore may be a source of pigmented head spots in Ednrb
mutants (Adameyko et al., 2012). The lack of any pigmentation in
the trunk indicates that both Schwann cell precursor derived and
other lineages of melanoblasts in that region require Endothelin
for development.
In chickens, the function of the endothelin receptor is shared
by two different homologs. Ednrb is expressed by neural crest
precursors prior to commitment to the melanocytic lineage and
Ednrb2 is expressed in migrating melanoblasts (Nataf et al., 1996;
Lecoin et al., 1998). Thus, the role of avian Ednrb2 seems more
homologous to mammalian Ednrb (Pla et al., 2005). In chick
experiments, Ednrb2 was required for melanoblasts to enter the
dorsal-lateral pathway and the ectopic expression of Ednrb2 in
neuronal neural crest cell precursors caused them to switch from
the ventral pathway to the dorsal-lateral pathway (Harris et al.,
2008). An inverted duplication present in the chicken genome in
several breeds leads to the over-expression of Edn3 (Dorshorst
et al., 2012). In these chick embryos, melanoblasts migrate
aberrantly along the ventral pathway, in addition to the expected
dorsal-lateral pathway (Faraco et al., 2001). This demonstrates
that endothelin signaling directs melanoblast migration.
It is not known exactly why melanoblasts fail to persist
in Ednrb null mouse embryos. Apoptotic melanoblasts were
not found in the melanocyte staging area of Ednrb mutants,
but these cells may have been difficult to detect (Lee et al.,
2003) and it is likely that endothelins do stimulate melanocyte
survival/proliferation. Many different in vitro experiments have
shown that Edn3 increases cell proliferation of neural crest cell
progenitors and melanoblasts in culture (Reid et al., 1996; Lahav
et al., 1998; Dupin et al., 2000; Real et al., 2006). In addition,
transgenic over-expression of the Edn3 ligand in the skin
increased dermal and epidermal melanoblast numbers during
embryogenesis (Garcia et al., 2008). However, melanoblasts in
the dermis were more strongly stimulated than melanoblasts in
the epidermis. Similarly, the over-expression of Edn3 in chickens
causes intense hyper-pigmentation of the dermis (Dorshorst
et al., 2012). In mice, and most other mammals besides humans,
melanocytes persist in the post-natal dermis in the tail and ears
and, in smaller numbers, in the trunk (Fitch et al., 2003; Van
Raamsdonk et al., 2004). These cells probably require on-going
endothelin signaling for support (Garcia et al., 2008; Hyter et al.,
2013).
THE RELATIONSHIP BETWEEN EDNRB
AND Gαq/11 DURING MOUSE
DEVELOPMENT
Because homozygous loss of Ednrb prevented all Gαq and Gα11
generated skin darkening in the Dsk mice, it was hypothesized
that Ednrb signals through Gαq/11 in melanocytes (Van
Raamsdonk et al., 2004). Direct data concerning the coupling
of Ednrb to a specific Gα subunit in melanocytes is limited.
GPCRs can couple to multiple Gα or Gβγ subunits [reviewed
in (Hermans, 2003)]. In reconstituted phospholipid vesicles
(Doi et al., 1999) and Chinese hamster ovary cells (Okamoto
et al., 1997), Ednrb stimulated phospholipase C and inhibited
adenylyl cyclase, through Gαq and Gαi, respectively. A deletion
in the C terminus of Ednrb, and the EdnrbG57S and EdnrbR319W
mutations, impair Gαi signaling, but not Gαq (Okamoto et al.,
1997; Fuchs et al., 2001). In contrast, an EdnrbW276C mutation
impairs Gαq coupling, but not Gαi (Imamura et al., 2000).
In human kidney 293 cells, EDN3 increased GTP binding
of Gα13 (Kitamura et al., 1999). In the cellular context of
melanocytes, the treatment of a cell line expressing EDNRB
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with EDN3 increased inositol 1,4,5-triphosphate and intra-
cytoplasmic calcium concentrations, which supports a role for
Gαq (Kang et al., 1998). These data high-light the promiscuity
of Ednrb.
If all of the effects of Ednrb activation in melanocytes were
generated through Gαq/11, then the complete knockout of Gnaq
and Gna11 would be expected to have the same phenotype
as Ednrb null mice, i.e., severe hypo-pigmentation. A double
knockout of Gnaq and Gna11 is lethal in mid-gestation in mice,
however, the knockout of a single allele of Gnaq is enough to
reduce the pigmentation of the adult dermis (Van Raamsdonk
et al., 2004). The presence of melanoblasts was noted at E18.5 in
a conditional knockout of Gnaq and Gna11 made specifically in
the neural crest lineage, but the number and distribution of these
melanoblasts was not described (Dettlaff-Swiercz et al., 2005).
A similar conditional knockout of Ednrb in the neural crest
lineage eliminated melanocytes in the trunk (Druckenbrod et al.,
2008).
There are several possible explanations for why Gnaq and
Gna11 conditional knockout in the neural crest lineage did not
completely eliminate melanoblasts. One is that Ednrb does not
couple to Gαq/11 in melanoblasts and the similarities in the
effects of Edn3 over-expression and Gαq/11 hyper-activity are just
coincidental. We think this is unlikely. Another explanation is
that in the absence of Gαq/11, Ednrb receptors activate other
G protein alpha subunits, which buffers the system. A third
possibility is that with four alleles of Gnaq and Gna11, Cre is not
as effective at eliminating all Gαq/11 as compared to Ednrb. There
is no data yet to distinguish between these possibilities.
However, in yet another striking similarity, both the over-
expression of Edn3 and the hyper-active Dsk alleles of Gαq/11
darken the mouse coat through increased post-natal pigment
production in hair follicles, using a mechanism that is
independent of melanocyte cell number (Garcia et al., 2008;
Van Raamsdonk et al., 2009a). Edn3 expression also correlates
with light and dark areas of cat coat color (Kaelin et al.,
2012). We point out that Schwann cell precursor derived
melanocytes localize to the dermis and hair follicles, and
these are both places where Edn3 and Gαq/11 gain-of-function
mutations generate developmental phenotypes. Meanwhile, the
inter-follicular epidermis is virtually unchanged as a result of
hyper-active Gαq/11 (Van Raamsdonk et al., 2004) and Schwann
cell precursor derived melanocytes do not colonize this part of
the epidermis (Deo et al., 2013). Thus, there is a correlation
between melanocyte lineage, response to Edn3 and Gαq/11
gain-of-function mutations, and melanocyte location during
development (Figure 1B).
THE RELATIONSHIP BETWEEN EDNRB
AND Gαq/11 IN MELANOMAGENESIS
Gαq/11 mutations play an obvious role in the development of
non-epithelial associated melanocytic lesions. There are specific
hotspot oncogenic mutations that are very frequently found in
a specific subset of melanocytic lesions, which do not involve
the epidermis. The role of Ednrb in melanoma is more difficult
to interpret. In fact, much of the data concerns the effects of
Ednrb on melanomas located in the epithelium, which implies
that the effects of Ednrb are not a result of Gαq/11 activation. As
Ednrb is probably able to couple to multiple G alpha subunits,
this is perhaps not surprising. In addition, signaling pathways
do not play the exact same roles in development as they do in
cancer, even while cancer often reactivates innate developmental
pathways. We will first summarize what has been reported about
Ednrb signaling in melanomas associated with the epithelium,
then discuss findings in uveal melanoma.
In general, EDNRB expression is positively correlated with
melanoma progression in cutaneous melanoma (Demunter et al.,
2001). Over-expression of EDNRB increased melanoma brain
metastases in mice orthotopically transplanted with human
melanoma cell lines (Cruz-Muñoz et al., 2012). The activation
of EDNRB by endothelins induces the expression of HIF-1α,
which leads to the up-regulation of vascular endothelial growth
factor and its receptor in primary and metastatic melanoma cell
lines, resulting in MAP kinase and AKT activation (Spinella
et al., 2012). These pathways up-regulate MCAM, a melanoma
cell adhesion molecule that promotes invasion and metastasis
(Williams et al., 2014).
The EDNRB inhibitors, BQ788, A192621, and Bonsentan
inhibit melanoma cell growth in vitro, in xenografts of human
melanomas in nude mice, and in some human patients, and
restore cell morphology to a more normal appearance (Bagnato
et al., 2004; Lahav et al., 2004; Berger et al., 2006; Kefford et al.,
2007; Cruz-Muñoz et al., 2012; Asundi et al., 2014; Wouters
et al., 2015). One recent study found that using a combination
of an antibody-drug conjugate targeting EDNRB, together with
small-molecule inhibitors of the MAP kinase pathway, increased
anti-tumor activity in BRAF/NRAS mutant cell lines and tumor
models (Asundi et al., 2014).
In contrast to these studies, putative loss-of-function germline
variants in EDNRB were associated with cyclin-dependent kinase
inhibitor 2A, CDKN2A, variants in familial melanoma cases in
a French population, but not in an Italian population (Spica
et al., 2011). EDNRB variants were not associated with sporadic
melanoma in either the French or Italian populations. Larger
studies and other populations are necessary to validate these
findings. Endothelin signaling has also been suggested to enhance
nucleotide excision repair following UV damage, and so a
deficiency in this process could possibly act synergistically with
a weak checkpoint (D’Orazio, 2015; von Koschembahr et al.,
2015).
Next, we will consider uveal melanoma. Although EDNRB
mutations have not been identified in uveal melanoma, the loss
of EDNRB expression in uveal melanoma has been correlated
with a worse prognosis in two different studies (Smith et al.,
2002; Onken et al., 2004). Because oncogenic Gαq/11 mutations
increase signaling, this is seems unexpected and contradictory
if one assumes that EDNRB signals through Gαq/11 in uveal
melanoma cells. However, there are two important points to
consider. One, it is not known yet whether Gαq/11 proteins with
constitutively active mutations require a receptor for activation
or, in fact, will even couple to a receptor given that they are
fixedly bound to GTP. EDNRB and Gαq/11 may become unlinked
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in the situation of uveal melanoma. If this is true, then it is
possible that a decrease in the expression of EDNRB may reduce
activation of the wildtype Gαq/11 proteins, which could somehow
enhance the effect of the mutant Gαq/11 proteins through a lack
of competition for downstream effectors.
The second point is that uveal melanoma patients without
GNAQ or GNA11 mutations tend to have a worse prognosis than
those with GNAQ or GNA11 mutations (Van Raamsdonk et al.,
2010). In a completely different hypothesis, GNAQ and GNA11
mutations could be early events that boost melanocyte cell
growth, but eventually it is necessary to down-regulate Gαq/11
signaling to achieve metastasis. This could be accomplished
by down-regulating EDNRB expression. Melanocytes without
GNAQ and GNA11 mutations would not need to go through
this step, having arisen through a different mechanism, and thus
progress more rapidly. In the future, more information on the
interactions of EDNRB with different mutant and wildtype G
protein alpha subunits is needed. In addition, it would be very
interesting to correlate tumor progression with both EDNRB
expression and the presence or absence of GNAQ and GNA11
mutations in uveal melanoma.
CONCLUSION
During development, both Ednrb and Gαq/11 regulate
melanoblasts migrating in the dermis with strikingly similar
effects. This suggests that they are closely linked together in the
same signaling pathway. In support of this, Ednrb is required
for the hyper-proliferative effects of the hyper-active Dsk Gnaq
and Gna11 alleles. Ednrb is also required for the development of
almost all melanocytes in the trunk, because all melanoblasts
must migrate through the dermis, even if their eventual
destination is the epidermis. Gain-of-function mutations in Edn3
and Gαq/11 increase melanocytes in the dermis and have little
effect on those in the inter-follicular epidermis. In addition,
gain-of-function mutations in Edn3 and Gαq/11 darken coat
color using a mechanism that is independent of cell number in
hair follicles. Thus, a pattern has emerged whereby melanocytes
whose activities are affected by gain-of-function mutations of
the Endothelin 3 ligand and Gαq/11 are the same subset that
arise from Schwann cell precursors. Furthermore, the forced
expression of the human GNAQQ209L oncogene in mouse
melanocytes only caused hyper-proliferation in the subset that
arise from Schwann cell precursors. This has led us to hypothesize
that in Schwann cell precursor derived melanocytes, Ednrb
signals through Gαq/11. Ednrb is promiscuous and may signal
through other G protein alpha subunits in melanomas located in
the inter-follicular epidermis.
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